Myeloma UK Collaboration

Myeloma UK logo

The CTRU are the co-ordinating centre for the Myeloma UK Early Phase Clinical Trials Network. This is a network of leading experts, hospitals and research centres across the UK set up to run a portfolio of prioritised early phase clinical trials to accelerate the testing of, and access to, new myeloma drugs.

The aims of the Clinical Trial Network are to:

  • Improve patient outcomes by developing and implementing strategic, clinically relevant and patient-centric clinical trials.
  • Improve the efficiency and speed with which new trials are set up and completed.
  • Produce results that change clinical practice through effective trial design and creating an environment that allows results to be adopted and diffused through the NHS as quickly as possible.
  • Ensure early access to experimental novel treatments by making the UK an internationally competitive place to conduct research in myeloma.
  • Develop strong and mutually beneficial collaborations with all relevant stakeholders.

Through increasing the speed at which novel drugs are tested and by ensuring that trial design reflects UK clinical practice and meets the needs of regulatory and reimbursement bodies as far as possible, we are increasing patient access to the newest and most innovative treatments in myeloma.

http://www.myeloma.org.uk/

Drug trials in set-up:

Topic / Disease Area  Acronym  Title
 Multiple Myeloma  MUKNine  OPTIMUM: A randomised phase II, pilot study, comparing two different approaches to the induction treatment of high risk (HR) myeloma
 Multiple Myeloma  MUKTen  PanDa VTD study: Phase 1/2a study of Panobinostat and Daratumumab with VTD for relapsed myeloma
 Multiple Myeloma  MUKTwelve A randomised phase II trial of Selinexor, cyclophosphamide and prednisone vs cyclophosphamide and prednisone in relapsed or refractory multiple myeloma (RRMM) patients.
 Multiple Myeloma  MUKFifteen A phase 1/2 study of Post-transplant Immunotherapy with immune checkpoint inhibition

Drug trials recruiting:

 Topic / Disease Area  Acronym  Title
 Multiple Myeloma MUKSeven  Pomalidomide Specific Targeting in Relapsed and Refractory Myeloma
 Multiple Myeloma MUKEight  A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and bortezomib
 Multiple Myeloma MUKEleven  VIRel: Viral immunotherapy in Relapsed/Refractory Multiple Myeloma (MM) - A Phase I Study to Assess the Safety and Tolerability of Reovirus in Combination with Lenalidomide and Pomalidomide

Drug trials in follow-up:

 Topic / Disease Area  Acronym  Title
 Multiple Myeloma MUKFive  A phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib and dexamethasone (CVD) for multiple myeloma patients at first relapse or refractory to no more than 1 line of treatment

Closed:

Topic / Disease Area Trial Acronym Title
Multiple Myeloma MUKOne A study to find the best starting dose of bendamustine, when given in combination with thalidomide and dexamethasone, in relapsed /refractory myeloma
 Multiple Myeloma MUKThree  A Phase I/IIa, Dose-Escalation, Study of CHR-3996 in Combination with Tosedostat in Participants with Relapsed, Refractory Multiple Myeloma
Multiple Myeloma MUKFour An open label, multi-centre, single arm, phase II trial to assess the activity, safety and tolerability of combination therapy with vorinostat, bortezomib and dexamethasone (V2D) in patients with relapsed multiple myeloma
 Multiple Myeloma MUKSix  A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients